Kala Pharmaceuticals (United States)
company in Waltham, United States
KALA Nasdaq
SEC CIK 1479419
Follow Kala Pharmaceuticals (United States)
Weekly email: filings, results
Net income
−$1.6M
+85.8% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$1.5M
+90.7% vs same quarter last year
Operating income
−$1.7M
+84.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$27M |
| FY24 | $0 | −$38.5M |
| FY23 | $0 | −$42.2M |
| FY22 | $3.9M | −$44.8M |
| FY21 | $11.2M | −$142.6M |
| FY20 | $6.4M | −$104.3M |
| FY19 | $6.1M | −$94.3M |
| FY18 | - | −$66.7M |
| FY17 | $0 | −$42.2M |
| FY16 | $0 | −$33.2M |
| FY15 | $45K | −$16.7M |
| FY14 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | −2099.3% | −1151.6% |
| FY21 | −1158.8% | −1268.7% |
| FY20 | −1512.6% | −1639.8% |
| FY19 | −1452.5% | −1553.3% |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | −35435.6% | −37071.1% |
| FY14 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | −$94.1M |
| FY18 | −$55.7M |
| FY17 | −$34.6M |
| FY16 | −$27.5M |
| FY15 | −$15.3M |
| FY14 | - |
- Kala Pharmaceuticals (United States)
- Healthcare median
Show the numbers
| Year | Kala Pharmaceuticals (United States) | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | −1151.6% | −80.4% |
| FY21 | −1268.7% | −71.9% |
| FY20 | −1639.8% | −62.2% |
| FY19 | −1553.3% | −46.3% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | −37071.1% | −38.4% |
| FY14 | - | −35.5% |